Zealand Pharma AS (OCSE:ZEAL)
kr 730 0 (0%) Market Cap: 51.57 Bil Enterprise Value: 43.49 Bil PE Ratio: 0 PB Ratio: 5.83 GF Score: 67/100

Zealand Pharma A/S Annual Shareholders Meeting Transcript

Mar 29, 2023 / 01:00PM GMT
Release Date Price: kr246.2 (+6.95%)
Martin Nicklasson

On behalf of the Board of Directors and Executive Board, I am pleased to welcome you to the Annual General Meeting 2023 of Zealand Pharma A/S. Today, the Board of Directors is represented by myself as Chairman and the Executive Board is represented by CEO, Adam Steensberg; and CFO, Henriette Wennicke. I would like to thank our shareholders for your attendance and continued support of the company. A year ago, we announced a change in strategy. We choose to prioritize investments in research and development. Zealand's core strength, as many of you already know, is the design and development of therapeutic peptides, and this has led to a rich pipeline of promising candidates targeting rare diseases, obesity and inflammation.

The company has demonstrated its ability to independently bring a product from discovery to market through the launch of Zegalogue in the U.S. However, Zealand also knows that to reach more patients in more regions around the world, the company should partner with global and regional leaders. Therefore, we scaled back Zealand's commercial operations and are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot